Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
about
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors.The role and therapeutic targeting of IL-6 in rheumatoid arthritis.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Sarilumab: First Global Approval.The role of interleukin-6 signalling and its therapeutic blockage in skewing the T cell balance in rheumatoid arthritis.Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.Treatment with Biologicals in Rheumatoid Arthritis: An Overview.Usability and Patient Preference Phase 3 Study of the Sarilumab Pen in Patients with Active Moderate-to-Severe Rheumatoid Arthritis.A review of sarilumab for the treatment of rheumatoid arthritis.Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.Identification of sarilumab pharmacodynamic and predictive markers in patients with inadequate response to TNF inhibition: a biomarker substudy of the phase 3 TARGET study.Comparative efficacy and tolerability of sarilumab 150 and 200 mg in patients with active rheumatoid arthritisSarilumab: patient-reported outcomes in rheumatoid arthritis
P2860
Q37704288-C6B1B1C9-6C08-4E1D-926A-F599DF55D75BQ38685086-E002A27B-508E-456F-A67B-92457A64EA12Q38745066-0B0582DD-262B-47BF-A014-0959D4596013Q39177162-6B616B54-70B7-460F-A01E-328F819EA276Q39215645-6D00D5B2-E29C-418F-8C70-E48BE9258E70Q40447501-C58C8F51-C9AD-4A0B-898C-D7CE1923C514Q47132835-5A5B064B-E79E-48D1-B22B-D09D707D36CEQ47325125-6D834747-8F25-427F-B987-8D696C2F102CQ50086851-FEF0846B-6CD5-4DD8-A21B-CBB2124C4059Q50334739-34261B7A-C3D8-4C8B-86EF-A6BF70B0B542Q52647587-3E032DCC-53CE-4164-902B-9204CB9EE362Q57330076-E50BB7A0-5463-4A95-B78D-065D07F749B1Q58735831-4C962218-61BF-456C-8C7B-91EC859AC14D
P2860
Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Sarilumab and Nonbiologic Dise ...... or Necrosis Factor Inhibitors.
@en
Sarilumab and Nonbiologic Dise ...... or Necrosis Factor Inhibitors.
@nl
type
label
Sarilumab and Nonbiologic Dise ...... or Necrosis Factor Inhibitors.
@en
Sarilumab and Nonbiologic Dise ...... or Necrosis Factor Inhibitors.
@nl
prefLabel
Sarilumab and Nonbiologic Dise ...... or Necrosis Factor Inhibitors.
@en
Sarilumab and Nonbiologic Dise ...... or Necrosis Factor Inhibitors.
@nl
P2093
P2860
P356
P1476
Sarilumab and Nonbiologic Dise ...... or Necrosis Factor Inhibitors.
@en
P2093
Deborah Bauer
Geraldo da Rocha Castelar-Pinheiro
Hubert van Hoogstraten
Jan Brzezicki
Janet van Adelsberg
Neil M H Graham
Pawel Hrycaj
Roy Fleischmann
P2860
P304
P356
10.1002/ART.39944
P577
2016-11-17T00:00:00Z